Your AI-Trained Oncology Knowledge Connection!
Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com
Omar Alkharabsheh, MD, discusses the growing treatment options for patients with myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, and how available agents have not induced a biological change or shown improvement in disease outcomes.
Findings from the phase 3 STAMPEDE, LATITUDE , and TITAN studies, brought to light the utility of second-generation androgen receptor inhibitors.
Shambavi Richard, MD, discusses pivotal data in the multiple myeloma paradigm, as well as remaining questions that future research efforts should aim to address.
Rafael F. Duarte, MD, PhD, FRCP, presents 2 real-world clinical cases in which the investigational monoclonal antibody narsoplimab demonstrated clinical benefit in patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Ajai Chari, MD, discusses the recent approval of belantamab mafodotin in relapsed/refractory multiple myeloma and other emerging agents under exploration in the space.
Investigators are evaluating the efficacy of enzastaurin, a PCKß inhibitor, in combination with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with high-risk DGM1–positive diffuse large B-cell lymphoma.
The majority of women at a high risk of developing ovarian cancer reported having a favorable attitude toward adopting a two-step risk-reducing early salpingectomy and delayed oophorectomy instead of a risk-reducing salpingo-oophorectomy.
The presence of MPL mutations in patients with essential thrombocythemia was found to be associated with an increased risk of myelofibrotic transformation.
Shagun D. Arora, MD, discusses findings from the phase 3 CANDOR, ICARIA-MM, and IKEMA studies which solidified the role of triplet regimens versus doublets in the relapsed/refractory multiple myeloma treatment landscape.
Luciano J. Costa, MD, discusses the emerging role of CAR T-cell therapy in relapsed/refractory multiple myeloma, investigational products such as ide-cel, orva-cel, and JNJ-4528, and early intervention strategies to manage the toxicities associated with these products.
Bradley A. McGregor, MD, sheds light on recently approved agents, as well as a multitude of novel therapies on the horizon, that appear to spell out a promising future for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
The novel phospholipid-drug conjugate CLR 131 induced a 100% overall response rate in patients with relapsed/refractory lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Richard D. Kim, MD, discusses the evolving treatment landscape of HCC, the approval of atezolizumab/bevacizumab, and other pivotal data in HCC.
Dae Won Kim, MD, discusses the NAPOLI-1 and NAPOLI-3 trials in metastatic pancreatic cancer, as well as the role of PARP inhibitors and remaining challenges in the space.
Kami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges that future research efforts should address.
Pretreatment with the investigational JAK2/FLT3 inhibitor pacritinib prior to allogeneic stem cell transplant was shown to be feasible and safe in patients with primary, post-polycythemia vera or post-essential thrombocythemia myelofibrosis.
Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the safety profile of the combination of spartalizumab, dabrafenib, and trametinib, the clinical implications of the biomarker data observed from this trial, and other emerging combinations on the horizon.
Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, discusses the management of immune-related adverse effects in patients who are receiving treatment with checkpoint inhibitors.
The American Society of Hematology has published new evidence-based guidelines to support older patients with acute myeloid leukemia and their health care providers in guiding treatment decisions.
In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in non–small cell lung cancer .
Paul A. Bunn, Jr, MD, discusses antibody-drug conjugates and how they are on the cusp of being introduced into the treatment paradigm for patients with HER2-mutant non–small cell lung cancer.
Anna C. Pavlick, DO, discusses the benefit of cemiplimab for patients with cutaneous squamous cell carcinoma (CSCC), the impact of these longer follow-up data, rare, but notable, toxicities that can arise with the agent, and ongoing research efforts aimed at increasing responses to immunotherapy in the CSCC space.
In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in mesothelioma.
Steven Lee Chang, MD, MS, discusses the impact of the COVID-19 pandemic on surgical practices, alternative options to surgery, and potential lessons to be learned from the pandemic.
In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in extensive-stage SCLC and limited-stage SCLC.
Shai Friedland, MD, discusses the novel multimodal FirstSight test, which showed promise in identifying colorectal cancer, as well as precancerous polyps and advanced adenomas.
Charu Aggarwal, MD, MPH, discusses the current state of treatment for patients with ALK-positive non–small cell lung cancer, the utility of liquid biopsy, and remaining questions that need to be addressed in the space.
Findings from a phase 2 study presented during the 2020 European Hematology Association Congress shed light on the first-in-class, investigational lysine-specific demethylase-1 inhibitor, bomedemstat, along with its promising clinical activity and tolerable safety profile as monotherapy in patients with advanced myelofibrosis.
Ruben A. Mesa, MD, FACP, discussed the current state of treatment in essential thrombocythemia and polycythemia vera, the underutilization of fedratinib in myelofibrosis, and emerging JAK inhibitors on the horizon.
Findings from a recent study published in European Urology show that salvage lymph node dissection alone is inadequate intervention for patients with prostate cancer and nodal recurrence.
